Compugen Ltd. maintains a 'Buy' rating as it progresses its lead drug COM701 for relapsed platinum-sensitive ovarian cancer, with phase 1/2 trial results expected in early 2027. The company's collaboration with AstraZeneca on rilvegostomig, which includes Compugen's COM902 TIGIT component, supports 12 ongoing phase 3 trials targeting various solid tumors, with key data anticipated in 2027. With $117.5 million in cash as of Q3 2026 and a burn rate that supports operations into 2029, Compugen is well-funded to advance its clinical programs and upcoming catalysts.
Compugen's drug development progress provides context for the health sector's market activity on Pluang. For readers following health stocks, here is Pluang's market snapshot as of Nov 11, 2026 00:02 WIB: out of 150 priced health-sector US stocks, 27 rose and 122 fell. Notable movers include BNGO at USD 1.25 with a 7.76% increase and 100% sell order activity, RXRX at USD 3.52 down 7.36% with 100% buy order activity, and ACAD at USD 17.71 up 7.33% with a typical hold time of 77 days.
As of October 31, 2026, EssilorLuxottica disclosed its total number of shares at 464,247,548 and actual voting rights at 458,376,127 after deducting treasury shares. The company enforces a 31% voting rights cap per shareholder, as outlined in its sta...
EssilorLuxottica disclosed its share capital and voting rights as of October 31, 2026, reporting 464,247,548 shares outstanding and 458,376,127 real voting rights excluding treasury shares. The company applies a 31% cap on voting rights per sharehold...
The global peptide therapeutics market is projected to grow from $112.2 billion in 2026 to $229.32 billion by 2036, at a CAGR of 7.4%. Growth is fueled by expanding use of GLP-1 and incretin therapies, advances in peptide engineering, new oncology ap...
Science 37, a direct-to-patient clinical research site, was named a BioSpace 2027 Best Place to Work, recognized for its innovative culture and commitment to clinical quality. The company’s model brings clinical trials to patients' homes, improving a...
Book Leopard, a new AI software, enables authors and publishers to create professional-quality Amazon book marketing materials in seconds for a one-time fee of $49, drastically reducing costs from over $1,000 and weeks of waiting. The tool generates ...
